Clinical trials: PD-1
Rectal Cancer
Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer
This is a single-arm, prospective, multicenter study evaluating a novel neoadjuvant treatment strategy for patients with early, mid-low rectal adenocarcinoma that is microsatellite stable (MSS).
- Trial name
- mRCAT-E (NCT07068763)
- Testing
- Lymph-node-sparing short-course radiotherapy, Capecitabine, PD-1/CTLA-4 inhibitor (Aiparolitoworixureli injection)
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sir Run Run Shaw Hospital
Colorectal Cancer, Pancreatic Cancer
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic colorectal cancer who have exposure to 2 or more lines of chemotherapy, to…
- Trial name
- NCT04117087
- Testing
- KRAS peptide vaccine, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
This is an open-label, single-arm, single-center clinical study to investigate the safety and efficacy of fuquinitinib combined with PD-1 inhibitors and first-line chemotherapy in the treatment of inoperable HER2-negative…
- Trial name
- G/GEJ cancer (NCT06158919)
- Testing
- Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Parkinson Disease, Multiple System Atrophy
Diagnostic and Prognostic Biomarkers in Parkinson Disease
The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- PROBE (NCT00653783)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Parkinson Study Group
Pharmacokinetics, Solid Tumor
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
The purpose of this study is to assess the safety and pharmacokinetics of boserolimab (MK-5890) when administered alone and in combination with pembrolizumab (MK-3475) in adults.
- Conditions
- Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
- Trial name
- NCT03396445
- Testing
- Boserolimab, Pembrolizumab, Pemetrexed
- Where
- 18 sites in United States, Chile and 5 more
- Volunteers
- 182 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
The main goal of this study is to establish the proportion of patients with objective response to zimberelimab/domvanalimab in PD-1 R/R melanoma patients.
- Trial name
- NCT05130177
- Testing
- Zimberelimab, Domvanalimab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Diwakar Davar
Advanced Gastric Cancer
Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer
The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus Providing More Options for Patients With Advanced…
- Trial name
- NCT03954756
- Testing
- Apatinib and PD1
- Volunteers
- 35 people
- Sponsor
- Henan Cancer Hospital
HCC
Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence.
- Trial name
- NCT06311929
- Testing
- PD-1 monoclonal antibody and lenvatinib, PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chen Xiaoping
Bladder Cancer
Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
This phase II trial studies how well fluorine F 18 Ara-G positron emission tomography (PET)/magnetic resonance (MR) imaging works in measuring clinical response to atezolizumab or patients with cancer receiving standard of care…
- Trial name
- NCT03007719
- Testing
- Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Lawrence Fong
Hepatocellular Carcinoma (HCC)
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
This is a study to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma…
- Trial name
- NCT03071094
- Testing
- Pexastimogene Devacirepvec (Pexa Vec), Nivolumab
- Where
- 2 sites in France
- Volunteers
- 14 people
- Sponsor
- Transgene
Hepatocellular Carcinoma
PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.
- Trial name
- NCT04974281
- Testing
- PD-1 and Lenvatinib Plus TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Locally Advanced Non-Small Cell Lung Cancer
A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy
This is a phase II, open-Label, multi-centre study to determine the efficacy and safety of Camrelizumab plus apatinib in participants with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), who have not progressed…
- Trial name
- NCT04749394
- Testing
- Camrelizumab, PD-1 monoclonal antibody, Apatinib, VEGFR2 antibody
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chinese Academy of Medical Sciences
Gastric Cancer
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
The purpose of the study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with PD-1 inhibitors and chemoradiotherapy, in comparison with adjuvant chemotherapy only, in D2/R0 resected pN3 gastric or…
- Trial name
- NCT04997837
- Testing
- PD-1 inhibitor, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 433 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer (NSCLC)
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
Evaluation of FDG PET/CT to image immunotherapy response in adult thoracic cancer. Compare pre- and post-treatment primary tumor uptake for FDG-PET/CT and correlate with clinical markers of response.
- Trial name
- NCT02608528
- Testing
- [18F]fluoroglucose(FDG)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Edema, Erythema
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
This phase II trial studies how well pembrolizumab works in treating patients with stage IV inflammatory breast cancer or triple-negative breast cancer that has spread to other places in the body (metastatic) or has come back…
- Conditions
- Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative
- Trial name
- NCT02411656
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Any Advanced Solid Tumors, Triple Negative Breast Cancer
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: Safety and tolerability of NT-I7 in combination with pembrolizumab Maximum Tolerated Dose (MTD) and/or the…
- Conditions
- Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04332653
- Testing
- NT-I7, pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 215 people
- Sponsor
- NeoImmuneTech
Squamous Cell Carcinoma of Anal Canal
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
The purpose of this study is to assess the efficacy of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemotherapy.
- Trial name
- NCT03597295
- Testing
- Retifanlimab
- Where
- 46 sites in United States, Belgium and 7 more
- Volunteers
- 94 people
- Sponsor
- Incyte Corporation
Chordoma
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery (SRS) in treating patients with chordoma that has come back or spread from where it started to other places in the body.
- Trial name
- NCT02989636
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sarcoma
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
- Trial name
- TNT (NCT03886311)
- Testing
- Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Breast Cancer
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not…
- Trial name
- NCT05374512
- Testing
- Dato-DXd, Paclitaxel, Nab-paclitaxel
- Where
- 228 sites in United States, Argentina and 21 more
- Volunteers
- 644 people
- Sponsor
- AstraZeneca